摘要
目的:探讨三阴性乳腺癌(TNBC)HER2(0/1+)和HER2(2+)两组中CK5/6、EGFR、VEGF、COX-2和TOPⅡα的表达差异及其临床意义。方法:收集2010年1月~2014年12月TNBC患者HER2(0/1+)组30例,HER2(2+)组15例,采用免疫组织化学方法检测CK5/6、EGFR、VEGF、COX-2和TOPⅡα的表达。结果:与HER2(2+)组比较,HER2(0/1+)组中CK5/6、EGFR、VEGF、COX-2和TOPⅡα的表达均偏高,但不具有统计学差异(P〉0.05);且与患者年龄、肿瘤大小、病理学类型及分级、淋巴结转移、脉管侵犯均无相关性(P〉0.05)。结论:TNBC HER2(0/1+)和HER2(2+)两者存在一些基因表达差异,可能为临床靶向治疗药物的选择提供理论依据。
Objective: To investigate the expression difference of CK5 /6,EGFR,VEGF,COX-2,TOPⅡα genes and their clinical significance between HER2( 0 /1 +) and HER2( 2 +) in the triple-negative breast cancers( TNBC). Methods: Thirty cases of TNBC with HER2( 0 /1 +) and 15 with HER2( 2 +) were included. Immunohistochemistry was performed to detect the expression of CK5 /6,EGFR,VEGF,COX-2 and TOPⅡα in the tissue specimens obtained from the TNBC cases. Results: Up-regulated expression of CK5 /6,EGFR,VEGF,COX-2 and TOPⅡα was observed in cases of HER2( 0 /1 +),yet the difference was not statistically significant,and expression of these genes was not correlated with the patient's ages,tumor size,type of pathology,histology grade,lymph node metastasis and vascular invasion( P〈0. 05). Conclusion: Expression of HER2( 0 /1 +) appears somewhat different from that of in TNBC,and this biological marker may be an important theoretical support to molecular target therapy for TNBC.
出处
《皖南医学院学报》
CAS
2016年第1期22-25,共4页
Journal of Wannan Medical College
基金
皖南医学院中青年科研基金项目(WK201513)
关键词
三阴性乳腺癌
HER2
表达
差异
triple-negative breast cancer
HER2
expression
differences